Insomnia: Causes, Brain Mechanisms, Medication & CBT-I Treatment

You have been exhausted all day, but the moment your head hits the pillow, your mind shifts into overdrive. It jumps from tomorrow's meeting to last month's bills to something that happened a decade ago. You glance at the clock: 2 a.m. You turn over and a single thought surfaces: "Tonight is ruined."

If this scene plays out three or more nights per week and has been going on for longer than three months, it meets the clinical definition of chronic insomnia disorder. Global prevalence estimates place chronic insomnia at roughly 10% to 15% of the adult population, making it one of the most common complaints in any mental health clinic. Many people trace their insomnia back to a period of high stress, and the confusing part is that the stress eventually passed but the sleeplessness did not. It is as though the brain forgot how to fall asleep naturally.

This article starts from that core question, why does insomnia become chronic, and works outward: what the brain is doing during insomnia, which treatments carry the strongest evidence, and why every international guideline places cognitive behavioral therapy ahead of medication.

What Is Insomnia Disorder?

Insomnia disorder is more than "not sleeping well." The DSM-5 requires all of the following for a diagnosis^[1]:

• Dissatisfaction with sleep quantity or quality, manifesting as difficulty initiating sleep, difficulty maintaining sleep (frequent awakenings or difficulty returning to sleep), or early-morning awakening
• The sleep disturbance causes clinically significant distress or impairment in daytime functioning (fatigue, poor concentration, mood instability, reduced productivity)
• The difficulty occurs despite adequate opportunity and circumstances for sleep
• The disturbance occurs at least three nights per week for at least three months (chronic insomnia)
• The problem is not better explained by another sleep disorder, substance use, or another mental disorder

That last point matters more than most people realize. Many individuals believe they "just have insomnia," but a thorough evaluation sometimes reveals an underlying condition such as obstructive sleep apnea, restless legs syndrome, or unrecognized anxiety or depression. This is why insomnia assessment requires more than a single question about how long it takes you to fall asleep.

Why Does Insomnia Become Chronic? The 3P Model

The most practical framework for understanding chronic insomnia is Spielman's 3P model^[2]:

Predisposing factors. Traits that lower your threshold for insomnia. These include a naturally high-arousal nervous system, an anxious temperament, or a family history of sleep difficulties. These factors alone do not necessarily cause insomnia, but they make you more vulnerable.

Precipitating factors. The specific event that triggers the first episode of insomnia. A spike in work pressure, bereavement, relocation, jet lag, or illness. For most people, sleep recovers once the stressor resolves. For some, it does not.

Perpetuating factors. This is where chronic insomnia truly lives. When you start going to bed earlier out of fear of not sleeping, scrolling your phone in bed while waiting for drowsiness, napping during the day, or drinking more coffee to power through fatigue, each of these behaviors seems logical in the moment but progressively erodes the brain's association between bed and sleep. Over time, even after the original stressor has disappeared, the insomnia persists because the perpetuating behaviors have taken on a life of their own.

The 3P model makes it clear that insomnia is not a willpower problem. You are not "failing to relax." Your brain has learned, through a chain of well-intentioned but counterproductive habits, to stay awake in bed.

What Happens in the Brain

The neuroscientific core of insomnia disorder is hyperarousal. Research shows that individuals with chronic insomnia are not simply awake at night; their brains are in a heightened state of activation around the clock^[3].

HPA axis overactivation. The 24-hour cortisol rhythm in chronic insomnia patients is shifted, with evening cortisol levels running higher than normal. This means the body is still in "alert mode" at the very time it should be winding down for sleep.

Default mode network hyperactivity. Neuroimaging studies show that when insomnia patients attempt to fall asleep, the default mode network, the brain circuitry responsible for internal dialogue and ruminative thinking, remains significantly more active than in good sleepers^[3]. This is the neural correlate of the racing thoughts that flood in the moment you lie down.

Reduced GABA. GABA is the brain's primary inhibitory neurotransmitter, responsible for "applying the brakes." Magnetic resonance spectroscopy (MRS) studies have found that GABA concentrations in the anterior cingulate cortex are significantly lower in insomnia patients compared to healthy controls^[3]. With weaker brakes, the brain struggles to slow down.

The orexin system. Orexins are neuropeptides secreted by the hypothalamus that promote wakefulness. Under normal conditions, orexin activity peaks during the day and subsides at night. In chronic insomnia, orexin regulation is disrupted, potentially sustaining wakefulness well into the night. This pathway is the pharmacological target of a newer class of sleep medications known as orexin receptor antagonists.

Common Presentations of Insomnia

Insomnia does not look the same in everyone. Clinically, it can be grouped into three patterns:

Three clinical patterns of insomnia

Daytime symptoms are equally important: persistent fatigue yet an inability to nap (because of hyperarousal), scattered attention, poor memory, mood swings, and a noticeable drop in work performance. Many patients come to clinic with the primary complaint of "I have no energy during the day" rather than "I cannot sleep at night."

Treatment

Across every major international guideline, the first-line treatment for insomnia disorder is not medication. It is Cognitive Behavioral Therapy for Insomnia (CBT-I)^[4][5]. This is a critical point that deserves emphasis up front.

First-Line Treatment: CBT-I

CBT-I is not simply "relaxation training." It is a structured treatment program, typically delivered over 4 to 8 sessions of 30 to 60 minutes each, designed to dismantle the perpetuating factors identified in the 3P model. Its core components include:

Stimulus control. Rebuilding the brain's association between bed and sleep. The rules are straightforward: go to bed only when sleepy; if you have not fallen asleep within 15 to 20 minutes, get out of bed and do a low-stimulation activity until drowsiness returns; do not use the bed for anything other than sleep (no phone, no television, no work).

Sleep restriction. This sounds counterintuitive, but it is one of CBT-I's most powerful techniques. You first calculate your current actual sleep time (say, five hours), then compress your time in bed to match that number. This temporarily increases sleep pressure (sleep drive), making it easier to fall asleep and improving sleep efficiency. Time in bed is then gradually extended as sleep consolidates.

Cognitive restructuring. Addressing the thoughts that fuel insomnia. "I will definitely not sleep tonight." "Tomorrow will be a disaster." "My health is going to collapse." These catastrophic beliefs are themselves perpetuating factors. The therapist helps you identify and challenge them, replacing them with more realistic appraisals.

Sleep hygiene. Maintaining a consistent sleep schedule, avoiding caffeine after noon, controlling bedroom light and temperature, and reducing screen time in the hour before bed. Sleep hygiene alone has limited efficacy, but as one component of CBT-I, it provides a stable environmental foundation.

The evidence is unambiguous: CBT-I matches the short-term efficacy of sleeping pills, but its long-term outcomes are superior^[4]. More importantly, the skills learned through CBT-I stay with you permanently. They do not disappear when treatment ends. This is precisely why the American Academy of Sleep Medicine (AASM)^[4] and the European Insomnia Guideline^[5] both recommend CBT-I as first-line therapy.

Medication

When CBT-I is insufficient, unavailable, or when symptom severity demands immediate relief, medication is a reasonable option. The important principle is that sleeping pills should serve as a short-term bridge, not as the sole long-term solution.

Medications commonly used for insomnia

Z-drugs (zolpidem, zopiclone) remain the most widely prescribed hypnotics. They are fast-acting and short-duration, but carry a risk of tolerance, meaning higher doses may be needed over time to achieve the same effect. All international guidelines recommend limiting Z-drug use to short-term courses, typically no longer than four weeks^[6].

Suvorexant represents a newer pharmacological approach. By blocking orexin receptors, it reduces the wakefulness drive rather than enhancing GABA-mediated inhibition. Its advantage lies in a lower propensity for tolerance and dependence, making it a more viable option for patients who require longer-term pharmacotherapy.

Trazodone is widely used off-label for insomnia. Technically an antidepressant, its antihistamine and sedative properties at low doses (25 to 100 mg) make it a common alternative to Z-drugs, with the notable advantage of carrying no addiction potential.

If you are looking at over-the-counter melatonin rather than prescription sleep medication, read when to take melatonin, how dose matters, and who should be cautious. For melatonin, timing, evening light, and a fixed wake time often matter as much as the number of milligrams.

Repetitive Transcranial Magnetic Stimulation (rTMS)

rTMS research in insomnia has focused primarily on patients with comorbid depression. When rTMS is used to treat the depressive component, some patients experience concurrent improvements in sleep quality. However, the evidence for rTMS as a standalone treatment for primary insomnia is not yet sufficient to support its routine use. If your insomnia coexists with depression, rTMS may address both issues simultaneously.

When to Seek Professional Evaluation

There are several insomnia self-assessment instruments available, but most (such as the Insomnia Severity Index) are clinical tools best used under physician guidance. If you want a quick initial check on your overall mental health status, the K6 scale on this website can help screen for general psychological distress.

That said, any of the following situations warrants a direct clinic appointment:

• Insomnia has persisted for more than three months, and improving sleep hygiene has not helped
• Daytime fatigue is severe enough to compromise safety (e.g., drowsy driving) or relationships
• You have started self-medicating with over-the-counter sleep aids or alcohol
• A bed partner has observed loud snoring, breathing pauses, or leg jerking during your sleep
• Insomnia is accompanied by anxiety, depression, or significant mood changes

One important note: if you are currently on long-term sleeping medication and wish to stop, taper gradually under medical supervision. Abruptly discontinuing hypnotics can trigger rebound insomnia or withdrawal symptoms.

References

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). 2022.
2. Spielman AJ, Caruso LS, Glovinsky PB. A behavioral perspective on insomnia treatment. Psychiatr Clin North Am. 1987;10(4):541-553. PubMed
3. Riemann D, Nissen C, Palagini L, et al. The neurobiology, investigation, and treatment of chronic insomnia. Lancet Neurol. 2015;14(5):547-558. DOI · PubMed
4. Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(2):255-262. DOI · PubMed
5. Riemann D, Espie CA, Altena E, et al. The European Insomnia Guideline: an update on the diagnosis and treatment of insomnia 2023. J Sleep Res. 2023;32(6):e14035. DOI · PubMed
6. Sateia MJ, Buysse DJ, Krystal AD, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307-349. DOI · PubMed
7. Riemann D, Baglioni C, Bassetti C, et al. Insomnia. Lancet. 2022;400(10357):1047-1060. DOI · PubMed